People: The Medicines Co (MDCO.O)

Summary

Name	Age	Since	Current Position
Clive Meanwell	55	2012	Chairman of the Board, Chief Executive Officer
Glenn Sblendorio	57	2012	President, Chief Financial Officer, Director
William O'Connor	54	2013	Senior Vice President, Chief Accounting Officer
Paul Antinori	59	2006	Senior Vice President, General Counsel
Elizabeth Wyatt	65	2012	Lead Independent Director
William Crouse	70	2003	Independent Director
Robert Hugin	58	2003	Independent Director
John Kelly	70	2011	Independent Director
Armin Kessler	75	1998	Independent Director
Robert Savage	59	2011	Independent Director
Hiroaki Shigeta	69	2012	Independent Director
Melvin Spigelman	64	2005	Independent Director

» Insider Trading

Biographies

Name	Description
Clive Meanwell	Dr. Clive Meanwell, M.D., Ph.D., is Chairman of the Board, Chief Executive Officer of The Medicines Co. He has been a director since 1996. He has served as chief executive officer since February 2012, chief executive officer and president from October 2009 to February 2012, as chief executive officer from August 2004 to October 2009, as president from August 2004 to December 2004, as executive chairman from September 2001 to August 2004 and as chief executive officer and president from 1996 to September 2001. From 1995 to 1996, Dr. Meanwell was a partner and managing director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including senior vice president from 1992 to 1995, vice president from 1991 to 1992 and director of product development from 1986 to 1991. In the past five years, Dr. Meanwell has also served as a director of Endo Pharmaceuticals Holdings, Inc. Dr. Meanwell received an M.D. and a Ph.D. from the University of Birmingham, United Kingdom.
Glenn Sblendorio	Mr. Glenn P. Sblendorio is President, Chief Financial Officer, Director of The Medicines Co. From March 2006 to February 2012, he served as chief financial officer and executive vice president. From November 2005 until he joined the Company, Mr. Sblendorio served as a consultant to a company in the pharmaceutical industry. Prior to joining, Mr. Sblendorio was executive vice president and chief financial officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as senior vice president of business development. From 1998 to July 2000, Mr. Sblendorio was the chief executive officer and managing director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including vice president, finance of Roche Molecular Systems and head of finance-controller for Amgen/Roche Europe. Mr. Sblendorio currently serves as a director of Amicus Therapeutics, Inc., a biopharmaceutical company and chairman of the board of NuLens Ltd., a private ophthalmology company. Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.
William O'Connor	Mr. William B. O'Connor is Senior Vice President, Chief Accounting Officer of The Medicines Co. He joined in April 2006 as vice president, finance and controller. From April 2000 to February 2006, he was the vice president of finance for Eyetech Pharmaceuticals, Inc. From 1996 to April 2000, Mr. O'Connor worked for Trophix Pharmaceuticals, Inc., a biotech company that specialized in pain medications. Mr. O'Connor is a certified public accountant and received a B.S. in accounting from Fairleigh Dickinson University.
Paul Antinori	Mr. Paul M. Antinori is Senior Vice President, General Counsel of The Medicines Co. He also served as vice president from August 2004 to August 2006. From March 1998 to April 2002, Mr. Antinori was general counsel and a consultant to Physician Computer Network, Inc., a healthcare information technology company. Prior to March 1998, Mr. Antinori was a partner at the law firm of Gibbons, Del Deo, Dolan, Griffinger & Vecchione in Newark, New Jersey. Mr. Antinori received his B.A. from Boston College and his J.D. from the University of Virginia School of Law.
Elizabeth Wyatt	Ms. Elizabeth H.S. Wyatt is Lead Independent Director of The Medicines Co., since March 30, 2005. She has been a director since March 2005 and has served as lead director since September 2012. Prior to her retirement in 2000, Ms. Wyatt held several senior positions at Merck & Co., Inc., a pharmaceutical company, over the course of 20 years, including most recently, vice president, corporate licensing. Previously she had been a consultant and academic administrator, responsible for the Harvard Business School's first formal marketing of its executive education programs. She also serves as the vice chair of the Board of Sweet Briar College and chaired the Search Committee for the current President of Sweet Briar College. In the past five years, Ms. Wyatt has also served as a director of Ariad Pharmaceuticals, Inc. Ms. Wyatt received a B.A. from Sweet Briar College, a M.Ed. from Boston University and an M.B.A. from Harvard Business School.
William Crouse	Mr. William W. Crouse is Independent Director of The Medicines Co., since April 22, 2003. From January 1994 to December 2011, Mr. Crouse was a general partner at HealthCare Ventures, a venture capital firm with a focus on biotechnology companies. From 1987 to 1993, Mr. Crouse served as worldwide president of Ortho Diagnostic Systems, a subsidiary of Johnson & Johnson that manufactures diagnostic tests for hospitals, and a vice president of Johnson & Johnson International. Before joining Johnson & Johnson, Mr. Crouse was a division director of DuPont Pharmaceuticals Company, where he was responsible for international operations and worldwide commercial development activities. Before joining Dupont, he served as president of Revlon Health Care Group's companies in Latin America, Canada, and Asia/Pacific. He also held numerous management positions at E.R. Squibb & Sons, a pharmaceutical company. Mr. Crouse is currently a member of the Board of Trustees of the New York Blood Center. In the past five years, he has also served as a director of Targanta Therapeutics Corporation. Mr. Crouse received a B.S. in finance and economics from Lehigh University and an M.B.A. from Pace University.
Robert Hugin	Mr. Robert J. Hugin is Independent Director of The Medicines Co., since April 22, 2003. Since June 2011, Mr. Hugin has served as chairman and chief executive officer of Celgene Corporation, a biopharmaceutical company focused on cancer and immunological diseases. Mr. Hugin was president and chief executive officer of Celgene from June 2010 to June 2011. From May 2006 to June 2010, Mr. Hugin served as the president and chief operating officer of Celgene, and from June 1999 to May 2006, Mr. Hugin served as the senior vice president and chief financial officer of Celgene. From 1985 to 1999, Mr. Hugin held multiple positions with J.P. Morgan & Co. Inc., a global investment banking firm. Mr. Hugin is a director of Celgene Corporation and Atlantic Health System, Inc. He also serves as Chairman of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of Princeton University, The Darden Foundation, University of Virginia and of Family Promise, a national non-profit network assisting homeless families. Mr. Hugin received an A.B. degree from Princeton University in 1976 and an M.B.A. from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.
John Kelly	Mr. John C. Kelly is Independent Director of The Medicines Company., since April 26, 2011. From October 2009 to February 2010, Mr. Kelly served as senior vice president, finance of Pfizer Inc. From March 2008 to October 2009, Mr. Kelly served as vice president and controller at Wyeth and from June 2002 to March 2008, he served as vice president, financial operations of Wyeth. Prior to joining Wyeth in 2002, he spent more than 35 years in public accounting at Arthur Andersen in various leadership capacities, including as the partner in charge of audit and business consulting practices in the New York metropolitan area. Mr. Kelly is currently a director of C.R. Bard, Inc., a medical device company, and Horizon Blue Cross Blue Shield of New Jersey. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. Mr. Kelly received a B.S. in business administration and an M.B.A. in international finance from Seton Hall University.
Armin Kessler	Mr. Armin M. Kessler is Independent Director of The Medicines Co., since October 1998. Mr. Kessler joined after a 35-year career in the pharmaceutical industry, which included senior management positions at Sandoz Pharma Ltd. (now Novartis Pharma AG) in Switzerland, the United States and Japan and, most recently, at Hoffmann-La Roche, in Basel, Switzerland, where he was chief operating officer and head of the pharmaceutical division until he retired in 1995. Mr. Kessler currently also serves as a director of Actelion Pharmaceuticals Ltd., a Swiss publicly traded company. In the past five years, Mr. Kessler has also served as a director of Gen-Probe Incorporated. Mr. Kessler received degrees in physics and chemistry from the University of Pretoria, a degree in chemical engineering from the University of Cape Town, a law degree from Seton Hall University School of Law and an honorary doctorate in business administration from the University of Pretoria. Mr. Kessler is a registered patent attorney with the United States Patent and Trademark Office.
Robert Savage	Mr. Robert G. Savage is Independent Director of The Medicines Co. Since May 2003, Mr. Savage has served as president of Strategic Imagery LLC, a consulting company he owns. From February 2002 to April 2003, Mr. Savage was group vice president and president for the General Therapeutics and Inflammation Business of Pharmacia Corporation, a research-based pharmaceutical firm acquired by Pfizer Inc. in April 2003. From September 1996 to January 2002, Mr. Savage held several senior positions with Johnson & Johnson, including worldwide chairman for the Pharmaceuticals Group during 2001, company group chairman responsible for the North America pharmaceuticals business from 2000 to 2001, president, Ortho-McNeil Pharmaceuticals from 1998 to 2000 and vice president sales & marketing from 1996 to 1998. Mr. Savage also serves as a director for EpiCept Corporation and Savient Pharmaceuticals. In the past five years, Mr. Savage has also served as a director for Noven Pharmaceuticals and Panacos Pharmaceuticals, Inc. Mr. Savage received a B.S. in biology from Upsala College and an M.B.A. from Rutgers University.
Hiroaki Shigeta	Mr. Hiroaki Shigeta is Independent Director of The Medicines Co. He has been a director since April 2007 and served as lead director from May 2011 to September 2012. Mr. Shigeta served as a consultant from July 2006 to December 2007. From January 2005 until June 2006, he served as a consultant to various Japanese pharmaceutical companies. From October 1993 to December 2004, Mr. Shigeta served in a variety of senior management positions with Hoffman-La Roche, Inc. and its affiliates. From January 2003 to December 2004, Mr. Shigeta was the U.S. head, Far East relations of Hoffman-La Roche and from June 2002 to April 2003, he was a member of the board of Chugai Seiyaku KK, Tokyo, a majority-owned affiliate of Roche Holding of Switzerland. From January 2001 to May 2002, Mr. Shigeta served as chairman and representative director of Nippon Roche KK, a pharmaceutical company and a Japanese affiliate of Roche Holding of Switzerland. From October 1993 to December 2000, Mr. Shigeta was the president and chief executive officer of Nippon Roche KK. Mr. Shigeta currently is a director of MediciNova, Inc., a biopharmaceutical company. Mr. Shigeta received a B.A. in economics from Momoyama Gakuin University in Osaka, Japan and a B.Sc from Haas Business School, University of California at Berkeley.
Melvin Spigelman	Dr. Melvin K. Spigelman M.D., is Independent Director of The Medicines Co., since September 29, 2005. Since January 2009, Dr. Spigelman has served as president and chief executive officer of the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. From June 2003 to January 2009, Dr. Spigelman served as director of research and development of the Global Alliance for TB Drug Development. Before joining the Global Alliance for TB Drug Development, Dr. Spigelman was the president of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001, Dr. Spigelman served as a vice president, global clinical centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma, and from 1992 to 2000, Dr. Spigelman was the vice president of research and development at Knoll. Dr. Spigelman serves as a director of Synergy Pharmaceuticals Inc., where he is a member of the audit and compensation committees and chair of the external communications oversight committee. Dr. Spigelman received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine.

Basic Compensation

Name	Fiscal Year Total
Clive Meanwell	5,954,650
Glenn Sblendorio	2,766,440
William O'Connor	959,738
Paul Antinori	1,608,900
Elizabeth Wyatt	--
William Crouse	--
Robert Hugin	--
John Kelly	--
Armin Kessler	--
Robert Savage	--
Hiroaki Shigeta	--
Melvin Spigelman	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Clive Meanwell	933,000	4,308,422
Glenn Sblendorio	269,555	1,277,572
William O'Connor	0	0
Paul Antinori	184,500	684,625
Elizabeth Wyatt	0	0
William Crouse	0	0
Robert Hugin	0	0
John Kelly	0	0
Armin Kessler	0	0
Robert Savage	0	0
Hiroaki Shigeta	0	0
Melvin Spigelman	0	0

Insider Trading

Name	Shares Traded	Price
ANTINORI PAUL MICHAEL	9,283	$33.29
ANTINORI PAUL MICHAEL	50,000	$33.28
ANTINORI PAUL MICHAEL	50,000	$22.47
ANTINORI PAUL MICHAEL	50,690	$33.29
ANTINORI PAUL MICHAEL	9,283	$12.95
ANTINORI PAUL MICHAEL	50,690	$19.36
KELLY JOHN C	3,849	$0.00
KESSLER ARMIN M	3,849	$0.00
SHIGETA HIROAKI	3,849	$0.00
CROUSE WILLIAM W	3,849	$0.00
HUGIN ROBERT J	3,849	$0.00
WYATT ELIZABETH H S	3,849	$0.00
SPIGELMAN MELVIN K	3,849	$0.00
SAVAGE ROBERT G	3,849	$0.00
KESSLER ARMIN M	12,500	$23.00
KESSLER ARMIN M	8,750	$33.05
HUGIN ROBERT J	12,500	$23.00
SBLENDORIO GLENN P	2,709	$37.00
ANTINORI PAUL MICHAEL	30,000	$18.27
O CONNOR WILLIAM BERNARD	25,000	$35.00
O CONNOR WILLIAM BERNARD	4,654	$12.95
ANTINORI PAUL MICHAEL	30,000	$34.90
ANTINORI PAUL MICHAEL	5,000	$17.04
O CONNOR WILLIAM BERNARD	25,000	$19.98
O CONNOR WILLIAM BERNARD	4,654	$35.00

» Full list on Insider Trading

People: The Medicines Co (MDCO.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: